<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01586455</url>
  </required_header>
  <id_info>
    <org_study_id>NYMC 550</org_study_id>
    <secondary_id>NYMC IRB L-10,733</secondary_id>
    <nct_id>NCT01586455</nct_id>
  </id_info>
  <brief_title>Human Placental-Derived Stem Cell Transplantation</brief_title>
  <acronym>HPDSC</acronym>
  <official_title>A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to investigate the safety of human placental-derived
      stem cells (HPDSC) given in conjunction with umbilical cord blood (UCB) stem cells in
      patients with various malignant or nonmalignant disorders who require a stem cell transplant.
      Patients will get either full dose (high-intensity) or lower dose (low intensity) chemo- and
      immunotherapy followed by a stem cell transplantation with UCB and HPDSC.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>100 days</time_frame>
    <description>to evaluate the safety of human placental-derived stem cells (HPDSC) administered in conjunction with umbilical cord blood (UCB) stem cells in patients with malignant and non-malignant diseases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>donor chimerism</measure>
    <time_frame>1 year</time_frame>
    <description>donor chimerism will be assessed at set timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>engraftment</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>100 days and 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>100 days and 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Mucopolysaccharidosis I</condition>
  <condition>Mucopolysaccharidosis VI</condition>
  <condition>Adrenoleukodystrophy</condition>
  <condition>Niemann-Pick Disease</condition>
  <condition>Metachromatic Leukodystrophy</condition>
  <condition>Wolman Disease</condition>
  <condition>Krabbe's Disease</condition>
  <condition>Gaucher's Disease</condition>
  <condition>Fucosidosis</condition>
  <condition>Batten Disease</condition>
  <condition>Severe Aplastic Anemia</condition>
  <condition>Diamond-Blackfan Anemia</condition>
  <condition>Amegakaryocytic Thrombocytopenia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>related cord blood with ≥3/6 HLA match to the patient and related HPDSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>unrelated cord blood with ≥ 4/6 HLA match to the patient and unrelated HPDSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>unrelated cord blood with ≥4/6 HLA match to the patient but related to HPDSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>double unrelated cord blood units with ≥4/6 HLA match to patient and each other and unrelated HPDSC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Placental Derived Stem Cell</intervention_name>
    <description>Infusions of thawed HPDSC to be given following UCB infusion.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <other_name>HPDSC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &lt; 55 years of age

          -  Life expectancy greater than 3 months

          -  Lansky performance status ≥ 50% (children) or Karnofsky performance status ≥ 70%
             (adults) or ECOG performance status 0-2 (adults)

          -  DLCO &gt; 50 percent predicted

          -  Left ventricular ejection fraction &gt; 40% estimated

          -  Creatinine clearance or estimated GFR . 60 mL/min/1.73m2

          -  Serum bilirubin &lt; 1.5x upper limit of normal

          -  Transaminases &lt; 3x upper limit of normal

          -  Absence of uncontrolled infection

          -  HIV negative

        Exclusion Criteria:

          -  Fanconi Anemia

          -  Myocardial infarction within 6 months prior to enrollment or has New York Heart
             Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities

          -  Uncontrolled infection

          -  Pregnant or breast-feeding females

          -  Received other investigational agents within 30 days prior to the start of the
             conditioning regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell S Cairo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2012</study_first_submitted>
  <study_first_submitted_qc>April 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>umbilical cord blood</keyword>
  <keyword>stem cell transplantation</keyword>
  <keyword>placental stem cell</keyword>
  <keyword>inborn errors of metabolism</keyword>
  <keyword>marrow failure</keyword>
  <keyword>Severe Combined Immunodeficiency Disease</keyword>
  <keyword>AML</keyword>
  <keyword>ALL</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Gaucher Disease</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Adrenoleukodystrophy</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Anemia, Diamond-Blackfan</mesh_term>
    <mesh_term>Leukodystrophy, Metachromatic</mesh_term>
    <mesh_term>Niemann-Pick Diseases</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type A</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type C</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Neuronal Ceroid-Lipofuscinoses</mesh_term>
    <mesh_term>Wolman Disease</mesh_term>
    <mesh_term>Leukodystrophy, Globoid Cell</mesh_term>
    <mesh_term>Mucopolysaccharidosis VI</mesh_term>
    <mesh_term>Fucosidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

